GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintara Therapeutics Inc (STU:3DMA) » Definitions » FCF Yield %

Kintara Therapeutics (STU:3DMA) FCF Yield % : -132.51 (As of May. 16, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Kintara Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Kintara Therapeutics's Trailing 12-Month Free Cash Flow is €-6.27 Mil, and Market Cap is €4.73 Mil. Therefore, Kintara Therapeutics's FCF Yield % for today is -132.51%.

The historical rank and industry rank for Kintara Therapeutics's FCF Yield % or its related term are showing as below:

STU:3DMA' s FCF Yield % Range Over the Past 10 Years
Min: -2099.83   Med: 0   Max: 0
Current: -132.51


STU:3DMA's FCF Yield % is ranked worse than
87.84% of 1554 companies
in the Biotechnology industry
Industry Median: -14.48 vs STU:3DMA: -132.51

Kintara Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.


Kintara Therapeutics FCF Yield % Historical Data

The historical data trend for Kintara Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintara Therapeutics FCF Yield % Chart

Kintara Therapeutics Annual Data
Trend Dec13 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -27.97 -117.70 -179.29

Kintara Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -75.62 -125.25 -89.41 -76.82 -205.28

Competitive Comparison of Kintara Therapeutics's FCF Yield %

For the Biotechnology subindustry, Kintara Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kintara Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kintara Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Kintara Therapeutics's FCF Yield % falls into.



Kintara Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Kintara Therapeutics's FCF Yield % for the fiscal year that ended in Jun. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-11.165 / 6.2272224
=-179.29%

Kintara Therapeutics's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-1.941 * 4 / 3.782124
=-205.28%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kintara Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Kintara Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Kintara Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kintara Therapeutics (STU:3DMA) Business Description

Traded in Other Exchanges
Address
9920 Pacific Heights Blvd, Suite 150, San Diego, CA, USA, 92121
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.

Kintara Therapeutics (STU:3DMA) Headlines

No Headlines